Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9719786 | 0.86 | AKR1C3 (0.51) | AKR1C3PTGS1NPC1RAB9APOLB | |
| SCHEMBL14280732 | 0.86 | AKR1C3 (0.48) | AKR1C3NPC1RAB9APOLBCYP2C9 | |
| SCHEMBL5105721 | 0.85 | KCNN4 (0.50) | AKR1C3PTGS1NPC1RAB9APOLB | |
| SCHEMBL11665378 | 0.85 | AKR1C3 (0.50) | AKR1C3PTGS1NPC1RAB9APOLB | |
| SCHEMBL7319456 | 0.85 | AKR1C3 (0.50) | AKR1C3PTGS1NPC1RAB9APOLB | |
| SCHEMBL1356271 | 0.84 | AKR1C3 (0.52) | AKR1C3NPC1RAB9APOLBCYP4F2 | |
| SCHEMBL3184688 | 0.84 | PPARA (0.53) | NPC1RAB9APOLBCYP2C9PPARA | |
| SCHEMBL10697799 | 0.83 | PKM (0.56) | AKR1C3PTGS1NPC1RAB9APOLB | |
| SCHEMBL29386858 | 0.82 | HDAC8 (0.51) | AKR1C3NPC1RAB9APOLBCYP2C9 | |
| SCHEMBL15577951 | 0.82 | F10 (0.49) | AKR1C3NPC1RAB9APOLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046119-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | Myriad Genetics, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008036733-A2 | METHODS FOR TREATMENT OF VESICLE TRANSPORT DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | claimed |
| WO-2008006099-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | claimed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020852-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020853-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-02 | — | — | US | disclosed |
| WO-2014015341-A2 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | VANDERBILT UNIVERSITY (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-2046119-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | Myriad Genetics, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008036733-A2 | METHODS FOR TREATMENT OF VESICLE TRANSPORT DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | disclosed |
| EP-1587798-A2 | GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS | Merck & Co., Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004064771-A2 | GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS | MERCK & CO., INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | AKR1C3 813/4885PTGS1 310/4885NPC1 4550/4885 |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 454/4885PTGS1 2521/4885NPC1 91/4885 |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 484/4885PTGS1 2642/4885NPC1 95/4885 |
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | CNR2, FAAH2, FAAH | AKR1C3 729/4885PTGS1 24/4885NPC1 3898/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | AKR1C3 1915/4885PTGS1 1251/4885NPC1 672/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 454/4885PTGS1 2521/4885NPC1 91/4885 |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | SLC6A3, SLC6A2, FKBP5 | AKR1C3 2969/4885PTGS1 4024/4885NPC1 1304/4885 |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | GRIN2A, GRIN2B, GRIN3A | AKR1C3 160/4885PTGS1 198/4885NPC1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.